title: Screening of KRAS Mutation in Pre- and Post-Surgery Serum of Patients Suffering from Colon Cancer by COLD-PCR HRM.
abstract: Genomic characterization of cell-free circulating tumour DNA (ctDNA) may offer an opportunity to assess clonal dynamics throughout the course of a patient's illness. The existence of KRAS driver mutations in colon cancer patients is determinant to decide their treatment and to predict their outcome. DNA is extracted automatically from 400 μL of serum using the MagNa Pure Compact with the Nucleic Acid Isolation Kit I. DNA amplification, COLD-PCR and HRM were performed in the same run in the Light Cycler 480.We found three different situations: pre- and post-surgical samples grouped with the negative control, pre-surgical samples appear to group with the positive control and the post-surgical samples appear to group with the negative control and finally both samples, pre- and post-surgical ones, appear to be grouped with the positive control. COLD-PCR HRM is a cost-effective way for screening one of the most common driver mutations to predict the worst prognosis in colorectal cancer.
authors.affiliation: Department of Clinical Biochemistry, Instituto de Biomedicina de Sevilla (IBiS/Csic/SAS/University of Seville), University Hospital Virgen del Rocío of Seville, Seville, Spain. elenatrujilloarribas@gmail.com.
authors.forename: Elena
authors.initials: E
authors.lastname: Trujillo-Arribas
authors.affiliation: Department of Clinical Biochemistry, Instituto de Biomedicina de Sevilla (IBiS/Csic/SAS/University of Seville), University Hospital Virgen del Rocío of Seville, Seville, Spain.
authors.forename: Hada C
authors.initials: HC
authors.lastname: Macher
authors.affiliation: Department of Clinical Biochemistry, Instituto de Biomedicina de Sevilla (IBiS/Csic/SAS/University of Seville), University Hospital Virgen del Rocío of Seville, Seville, Spain.
authors.forename: Pilar
authors.initials: P
authors.lastname: Jiménez-Arriscado
authors.affiliation: Coloproctologic Surgery Unit, Virgen del Rocío University Hospital, Seville, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: de la Portilla
authors.affiliation: Department of Clinical Biochemistry, Instituto de Biomedicina de Sevilla (IBiS/Csic/SAS/University of Seville), University Hospital Virgen del Rocío of Seville, Seville, Spain.
authors.forename: Patrocinio
authors.initials: P
authors.lastname: Molinero
authors.affiliation: Department of Clinical Biochemistry, Instituto de Biomedicina de Sevilla (IBiS/Csic/SAS/University of Seville), University Hospital Virgen del Rocío of Seville, Seville, Spain.
authors.forename: Juan M
authors.initials: JM
authors.lastname: Guerrero
authors.affiliation: Department of Clinical Biochemistry, Instituto de Biomedicina de Sevilla (IBiS/Csic/SAS/University of Seville), University Hospital Virgen del Rocío of Seville, Seville, Spain.
authors.forename: Amalia
authors.initials: A
authors.lastname: Rubio
mesh_terms: D003110:Colonic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000235:genetics*; D003362:Cost-Benefit Analysis; D004273:DNA, Neoplasm / Q000097:blood / Q000737:chemistry / Q000235:genetics*; D005820:Genetic Testing / Q000191:economics / Q000379:methods; D006801:Humans; D009154:Mutation; D016133:Polymerase Chain Reaction / Q000191:economics / Q000379:methods*; D011184:Postoperative Period; D057234:Preoperative Period; D011379:Prognosis; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D012680:Sensitivity and Specificity
chemical_list: D004273:DNA, Neoplasm; C117307:KRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)
keywords: Colorectal cancer; Genomic signature; KRAS mutation; cf-DNA